Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthtech Industry Analysis

UpdatedApr 15, 2026
DataAggregated Company Financials
Companies69
  • 7D-4.2%
  • 3M-28.6%
  • 1Y-37.6%
  • YTD-29.0%

Over the last 7 days, the Healthtech industry has dropped 4.2%, driven by Veeva Systems declining 7.8%. In contrast, HeartFlow has gained 8.1%. However, the industry is down 38% over the past year. Looking forward, earnings are forecast to grow by 22% annually.

Industry Valuation and Performance

Has the U.S. Healthtech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Apr 2026US$44.3bUS$13.6b-US$414,701,415.0030x-106.7x3.3x
Fri, 13 Mar 2026US$50.2bUS$13.5b-US$318,312,318.0032.1x-157.6x3.7x
Sun, 08 Feb 2026US$50.9bUS$13.6b-US$115,740,340.0041.8x-439.9x3.7x
Tue, 06 Jan 2026US$64.3bUS$13.6b-US$102,572,340.0053.6x-626.4x4.7x
Thu, 04 Dec 2025US$69.5bUS$13.6b-US$119,482,271.0054.9x-581.5x5.1x
Sat, 01 Nov 2025US$78.6bUS$13.1b-US$204,351,903.0058.9x-384.4x6x
Mon, 29 Sep 2025US$81.0bUS$13.2b-US$266,647,296.0059.3x-303.8x6.1x
Wed, 27 Aug 2025US$78.5bUS$13.1b-US$369,126,795.0060x-212.7x6x
Fri, 25 Jul 2025US$79.4bUS$13.3b-US$1,473,336,447.0061x-53.9x6x
Sun, 22 Jun 2025US$76.7bUS$13.2b-US$1,382,394,447.0053.5x-55.5x5.8x
Tue, 20 May 2025US$70.1bUS$13.1b-US$1,460,873,518.0054x-48x5.3x
Thu, 17 Apr 2025US$66.6bUS$13.2b-US$1,417,865,959.0050.3x-46.9x5.1x
Sat, 15 Mar 2025US$68.0bUS$13.2b-US$1,418,576,862.0059.1x-47.9x5.2x
Mon, 10 Feb 2025US$76.7bUS$12.9b-US$1,610,814,514.0065.8x-47.6x5.9x
Wed, 08 Jan 2025US$66.7bUS$12.9b-US$1,636,336,735.0055.6x-40.7x5.2x
Fri, 06 Dec 2024US$69.4bUS$12.8b-US$1,712,780,390.0059.8x-40.5x5.4x
Sun, 03 Nov 2024US$63.2bUS$13.5b-US$3,010,457,656.0049x-21x4.7x
Tue, 01 Oct 2024US$65.2bUS$14.0b-US$3,288,675,208.0053.3x-19.8x4.7x
Thu, 29 Aug 2024US$63.3bUS$13.9b-US$3,379,735,604.0058.4x-18.7x4.6x
Sat, 27 Jul 2024US$59.2bUS$13.7b-US$1,860,658,542.0053x-31.8x4.3x
Mon, 24 Jun 2024US$57.2bUS$13.7b-US$1,889,788,216.0047.3x-30.3x4.2x
Wed, 22 May 2024US$59.0bUS$12.8b-US$1,973,252,856.0046.8x-29.9x4.6x
Fri, 19 Apr 2024US$57.2bUS$12.7b-US$1,620,331,315.0046.5x-35.3x4.5x
Sun, 17 Mar 2024US$64.0bUS$14.3b-US$1,457,126,316.0048.8x-43.9x4.5x
Tue, 13 Feb 2024US$64.8bUS$13.8b-US$5,675,716,752.0062.1x-11.4x4.7x
Thu, 11 Jan 2024US$71.5bUS$18.3b-US$5,780,492,665.0055.1x-12.4x3.9x
Sat, 09 Dec 2023US$65.9bUS$18.3b-US$5,772,419,665.0052.1x-11.4x3.6x
Mon, 06 Nov 2023US$68.0bUS$18.3b-US$5,826,818,376.0052x-11.7x3.7x
Wed, 04 Oct 2023US$69.4bUS$18.0b-US$5,559,240,965.0052.4x-12.5x3.8x
Fri, 01 Sep 2023US$73.6bUS$18.0b-US$5,525,678,389.0050.1x-13.3x4.1x
Sun, 30 Jul 2023US$77.7bUS$17.8b-US$5,538,206,318.0062.2x-14x4.4x
Tue, 27 Jun 2023US$74.8bUS$17.7b-US$8,580,509,261.0062.1x-8.7x4.2x
Thu, 25 May 2023US$68.7bUS$17.7b-US$8,622,664,320.0057.7x-8x3.9x
Sat, 22 Apr 2023US$75.6bUS$17.4b-US$14,978,330,855.0060x-5.1x4.3x
Price to Earnings Ratio

-5.1x


Total Market Cap: US$75.6bTotal Earnings: -US$14,978,330,855.00Total Revenue: US$17.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthtech Industry Price to Earnings3Y Average -126.1x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 4.7x is higher than the industry's current PS ratio of 3.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare Services industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 8.0% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market4.44%
Healthcare2.18%
Healthtech-4.21%
Healthtech-4.21%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
WAY Waystar HoldingUS$24.689.0%
+US$389.1m		-32.8%PE42.2x
DOCS DoximityUS$23.909.3%
+US$376.8m		-54.7%PE18.4x
HTFL HeartFlowUS$29.237.9%
+US$184.4m		n/aPS14.2x
VEEV Veeva SystemsUS$167.300.4%
+US$119.2m		-24.2%PE30.1x
CERT CertaraUS$6.1513.3%
+US$110.4m		-54.5%PS2.3x

Latest News

TBRG
US$22.13
TruBridge
7D
26.3%
1Y
-8.3%
CCLD
US$2.87
CareCloud
7D
-11.1%
1Y
100.7%

CCLD: Cost Controls And AI Automation Will Offset Acquisition And Aircraft Spending

Analysts have reaffirmed their $3.25 price target on CareCloud, citing recent results as reasonable. However, they expressed concern that acquisitions, including a planned aircraft purchase for client visits, may be obscuring the company’s underlying revenue trends.
VEEV
US$167.30
Veeva Systems
7D
0.4%
1Y
-24.2%
SDGR
US$12.40
Schrödinger
7D
7.8%
1Y
-50.8%
HTFL
US$29.23
HeartFlow
7D
7.9%
1Y
n/a
WAY
US$24.68
Waystar Holding
7D
9.0%
1Y
-32.8%

WAY: AI Revenue Cycle Automation And Data Scale Will Support Future Earnings Power

Analysts have nudged their price target for Waystar Holding slightly lower to about $36.09 from around $36.77, reflecting small tweaks to assumptions on discount rate, long term revenue, growth, profit margin, and future P/E expectations. What's in the News Waystar launched an AI-powered solution aimed at identifying provider revenue affected by post payment recoupments, supported by a proprietary dataset covering more than 7.5 billion healthcare payment transactions and over US$2.4b in annual gross claims (Key Developments).
CERT
US$6.15
Certara
7D
13.3%
1Y
-54.5%
OPRX
US$6.40
OptimizeRx
7D
-1.5%
1Y
-21.8%
DOCS
US$23.90
Doximity
7D
9.3%
1Y
-54.7%

DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement

The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.
ACON
US$3.20
Aclarion
7D
-10.4%
1Y
-64.8%
GDRX
US$2.32
GoodRx Holdings
7D
8.4%
1Y
-47.9%

GDRX: Pharma Direct Pivot Will Reframe Prescription Headwinds Going Forward

Analysts have reset GoodRx's fair value and price targets sharply lower, with the average target moving from about $7.00 toward $3.50 as they factor in a higher discount rate, softer revenue growth and margin expectations, and a higher assumed future P/E multiple driven by pressure on the core prescription business alongside potential support from Pharma Direct. Analyst Commentary Recent research updates cluster around a consistent message: lower fair value estimates for GoodRx, but with a split between cautious and more constructive views on the path forward.
AIFF
US$1.58
Firefly Neuroscience
7D
-7.1%
1Y
-47.3%
ISPC
US$0.11
iSpecimen
7D
-22.9%
1Y
-91.5%
BFRG
US$0.94
Bullfrog AI Holdings
7D
-12.4%
1Y
-43.5%